

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number

10/564,614

Filing Date

May 30, 2006

First Named Inventor

Vladimir Subr

Art Unit

4161

Examiner Name

Kevin S. Orwig

Attorney Docket Number

J126-022 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		K. Ulbrich, et al. "Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterisation" J. Controlled Release 64, 2000, 63-79	
		B. Rihova, et al. " Polymeric drugs based on conjugates of synthetic and natural macromolecules II. Anticancer activity of antibody or (Fab) ₂ sub 2 targeted conjugates and combined therapy with immunomodulators" J. Controlled Release 64 (2000) 241-261	
		J. Kopecek, et al. " HPMa copolymer-anticancer drug conjugates: design, activity, and mechanism of action"	
		K. Ulbrich, et al. "Polymeric Conjugates of Drugs and Antibodies for Site-Specific Drug Delivery, Macromol. Symp"	
		J. Kopecek, et al., "HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action"	
		P.A. Vasey, et al., "HPMA co-polymer doxorubicin"	
		P.A. Vasey, et al., "Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic	
		P. J. Julyan, et al., "Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine", J. Controlled Release 37 (1999) 261-290	
		A. H. Thomson et al. "Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors"	
		L. W. Seymour et al., Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin.	

**Examiner
Signature**

/Kevin Orwig/

**Date
Considered**

03/08/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.O./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/564,614
Filing Date	May 30, 2006
First Named Inventor	Vladimir Subr
Art Unit	4161
Examiner Name	Kevin S. Orwig
Attorney Docket Number	J126-022 US

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		J. Clin, "Phase I clinical and pharmacokinetic study of PNU 166945, a novel water-soluble prodrug of paclitaxel"	
		M. I. M. Tenwagt, "Phase I clinical and pharmacokinetic study of PNU 166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs"	
		M. Bouma, Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5260 in infusion systems and its hemolytic potential	
		M.M. Tibben, "Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP 5260, by use of graphite-furnace Zeeman atomic-absorption"	
		B. Rihova et al., "Drug-HPMA-HuIg conjugates effective against human solid cancer"	

Examiner Signature	/Kevin Orwig/	Date Considered	03/08/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.O./